New York, Feb 2, 2026, 05:06 (EST) — Premarket
- Atossa Therapeutics is set to carry out a 1-for-15 reverse stock split starting Monday
- On Friday, the stock closed at $0.565, slipping roughly 6% from its previous close
- Investors are closely monitoring if the split will keep the company in Nasdaq compliance before the mid-February deadline
Atossa Therapeutics, Inc. is set to implement a one-for-fifteen reverse stock split on Monday, according to a Nasdaq notice. Following the split, the shares will trade under a new CUSIP in the U.S. securities system.
Why it matters now: the company is targeting a boost in its per-share price, which has been stuck below $1 for a while—a key threshold for staying listed. It recently announced a new deadline to meet compliance, pushed back to Feb. 17, 2026, according to a filing.
The shares most recently changed hands at $0.565, marking a 6.2% drop from the previous close, per market data. Adjusted for a simple split, that price equates to about $8.48 a share before any new trades.
Atossa announced in an SEC filing that its reverse stock split took effect at 12:01 a.m. Eastern on Feb. 2, with shares set to trade on a split-adjusted basis from the opening bell. The company confirmed it won’t issue fractional shares, opting to pay cash instead, calculated using the closing price from Jan. 30. It also plans proportional changes to equity awards and the terms of its Series B convertible preferred stock.
Reverse stock splits merge existing shares into a smaller number, pushing the price up without altering the company’s fundamental value. For micro-cap stocks, trading often turns volatile around the split, as liquidity and order sizes adjust.
Atossa’s proxy materials warned the reverse split might hurt liquidity and push up transaction costs, particularly if the stock price fails to climb post-split.
The Options Clearing Corporation announced that listed options will be adjusted. The option symbol will change to ATOS1, with contracts now representing a combination of new shares and cash in lieu for fractional entitlements.
Seattle-based Atossa is a clinical-stage biotech company specializing in oncology, particularly breast cancer.
The split alone won’t cure a sagging share price. Should selling pick up again and the stock slide back toward penny-stock territory, the Nasdaq listing issue could come back into play fast.
The immediate trigger will be the first regular-session trade in the post-split shares once U.S. markets open at 9:30 a.m. ET. Beyond that, investors are focused on Feb. 17, the next key deadline linked to Atossa’s Nasdaq compliance period.
